Advertisement

Index by author

April 01, 2023; Volume 51,Issue 4

A

  1. Amilon, Carl

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100
    2. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Open Access
      Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 464-479; DOI: https://doi.org/10.1124/dmd.122.001099

  2. Amory, John K.

    1. Relevance of Human Aldoketoreductases and Microbial β-Glucuronidases in Testosterone Disposition
      Abdul Basit, John K. Amory, Vijaya Saradhi Mettu, Cindy Yanfei Li, Scott Heyward, Parth B. Jariwala, Matthew R. Redinbo and Bhagwat Prasad
      Drug Metabolism and Disposition April 2023, 51 (4) 427-435; DOI: https://doi.org/10.1124/dmd.122.000975

  3. Andersson, Linda C.

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100

  4. Antonsson, Thomas

    1. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Open Access
      Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 464-479; DOI: https://doi.org/10.1124/dmd.122.001099

B

  1. Basit, Abdul

    1. Relevance of Human Aldoketoreductases and Microbial β-Glucuronidases in Testosterone Disposition
      Abdul Basit, John K. Amory, Vijaya Saradhi Mettu, Cindy Yanfei Li, Scott Heyward, Parth B. Jariwala, Matthew R. Redinbo and Bhagwat Prasad
      Drug Metabolism and Disposition April 2023, 51 (4) 427-435; DOI: https://doi.org/10.1124/dmd.122.000975

  2. Bhattacharya, Chandrali

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100

  3. Bragg, Ryan A.

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100

  4. Bumpus, Namandjé N.

    1. Open Access
      Biotransformation of Efavirenz and Proteomic Analysis of Cytochrome P450s and UDP-Glucuronosyltransferases in Mouse, Macaque, and Human Brain-Derived In Vitro Systems
      Abigail M. Wheeler, Benjamin C. Orsburn and Namandjé N. Bumpus
      Drug Metabolism and Disposition April 2023, 51 (4) 521-531; DOI: https://doi.org/10.1124/dmd.122.001195

C

  1. Chang, Qi

    1. CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells
      Weihong Yang, Huan Zhao, Yaojie Dou, Pei Wang, Qi Chang, Xiaomeng Qiao, Xiaofei Wang, Chen Xu, Zhe Zhang and Lirong Zhang
      Drug Metabolism and Disposition April 2023, 51 (4) 492-498; DOI: https://doi.org/10.1124/dmd.122.001111

  2. Cho, Sungjoon

    1. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
      Shuguang Ma, Sungjoon Cho, Srikumar Sahasranaman, Weiping Zhao, Jodie Pang, Xiao Ding, Brian Dean, Bin Wang, Jerry Y. Hsu, Joseph Ware and Laurent Salphati
      Drug Metabolism and Disposition April 2023, 51 (4) 436-450; DOI: https://doi.org/10.1124/dmd.122.001096

D

  1. Dean, Brian

    1. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
      Shuguang Ma, Sungjoon Cho, Srikumar Sahasranaman, Weiping Zhao, Jodie Pang, Xiao Ding, Brian Dean, Bin Wang, Jerry Y. Hsu, Joseph Ware and Laurent Salphati
      Drug Metabolism and Disposition April 2023, 51 (4) 436-450; DOI: https://doi.org/10.1124/dmd.122.001096

  2. De Cock, Pieter

    1. Predictive Performance of Physiologically Based Pharmacokinetic Modelling of Beta-Lactam Antibiotic Concentrations in Adipose, Bone, and Muscle Tissues
      Predictive Performance of Physiologically Based Pharmacokinetic Modelling of Beta-Lactam Antibiotic Concentrations in Adipose, Bone, and Muscle Tissues
      Pieter-Jan De Sutter, Pieter De Cock, Trevor N Johnson, Helen Musther, Elke Gasthuys and An Vermeulen
      Drug Metabolism and Disposition April 2023, 51 (4) 499-508; DOI: https://doi.org/10.1124/dmd.122.001129

  3. de Ligt, Rianne A.F.

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100

  4. De Sutter, Pieter-Jan

    1. Predictive Performance of Physiologically Based Pharmacokinetic Modelling of Beta-Lactam Antibiotic Concentrations in Adipose, Bone, and Muscle Tissues
      Predictive Performance of Physiologically Based Pharmacokinetic Modelling of Beta-Lactam Antibiotic Concentrations in Adipose, Bone, and Muscle Tissues
      Pieter-Jan De Sutter, Pieter De Cock, Trevor N Johnson, Helen Musther, Elke Gasthuys and An Vermeulen
      Drug Metabolism and Disposition April 2023, 51 (4) 499-508; DOI: https://doi.org/10.1124/dmd.122.001129

  5. Ding, Xiao

    1. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
      Shuguang Ma, Sungjoon Cho, Srikumar Sahasranaman, Weiping Zhao, Jodie Pang, Xiao Ding, Brian Dean, Bin Wang, Jerry Y. Hsu, Joseph Ware and Laurent Salphati
      Drug Metabolism and Disposition April 2023, 51 (4) 436-450; DOI: https://doi.org/10.1124/dmd.122.001096

  6. Dou, Yaojie

    1. CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells
      Weihong Yang, Huan Zhao, Yaojie Dou, Pei Wang, Qi Chang, Xiaomeng Qiao, Xiaofei Wang, Chen Xu, Zhe Zhang and Lirong Zhang
      Drug Metabolism and Disposition April 2023, 51 (4) 492-498; DOI: https://doi.org/10.1124/dmd.122.001111

E

  1. Ekdahl, Anja

    1. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Open Access
      Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 464-479; DOI: https://doi.org/10.1124/dmd.122.001099

G

  1. Garkaviy, Pavlo

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100

  2. Gasthuys, Elke

    1. Predictive Performance of Physiologically Based Pharmacokinetic Modelling of Beta-Lactam Antibiotic Concentrations in Adipose, Bone, and Muscle Tissues
      Predictive Performance of Physiologically Based Pharmacokinetic Modelling of Beta-Lactam Antibiotic Concentrations in Adipose, Bone, and Muscle Tissues
      Pieter-Jan De Sutter, Pieter De Cock, Trevor N Johnson, Helen Musther, Elke Gasthuys and An Vermeulen
      Drug Metabolism and Disposition April 2023, 51 (4) 499-508; DOI: https://doi.org/10.1124/dmd.122.001129

  3. Gopaul, V. Sashi

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100
    2. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Open Access
      Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 464-479; DOI: https://doi.org/10.1124/dmd.122.001099

  4. Gränfors, Malin

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100

H

  1. Heijer, Maria

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100

  2. Heyward, Scott

    1. Relevance of Human Aldoketoreductases and Microbial β-Glucuronidases in Testosterone Disposition
      Abdul Basit, John K. Amory, Vijaya Saradhi Mettu, Cindy Yanfei Li, Scott Heyward, Parth B. Jariwala, Matthew R. Redinbo and Bhagwat Prasad
      Drug Metabolism and Disposition April 2023, 51 (4) 427-435; DOI: https://doi.org/10.1124/dmd.122.000975

  3. Higuchi, Yuichiro

    1. The Unique Human N10-Glucuronidated Metabolite Formation from Olanzapine in Chimeric NOG-TKm30 Mice with Humanized Livers
      The Unique Human N10-Glucuronidated Metabolite Formation from Olanzapine in Chimeric NOG-TKm30 Mice with Humanized Livers
      Shotaro Uehara, Yuichiro Higuchi, Nao Yoneda, Hiroaki Kato, Hiroshi Yamazaki and Hiroshi Suemizu
      Drug Metabolism and Disposition April 2023, 51 (4) 480-491; DOI: https://doi.org/10.1124/dmd.122.001102

  4. Hsu, Jerry Y.

    1. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
      Shuguang Ma, Sungjoon Cho, Srikumar Sahasranaman, Weiping Zhao, Jodie Pang, Xiao Ding, Brian Dean, Bin Wang, Jerry Y. Hsu, Joseph Ware and Laurent Salphati
      Drug Metabolism and Disposition April 2023, 51 (4) 436-450; DOI: https://doi.org/10.1124/dmd.122.001096

I

  1. Inghardt, Tord

    1. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Open Access
      Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 464-479; DOI: https://doi.org/10.1124/dmd.122.001099

  2. Isin, Emre M.

    1. Open Access
      Unusual Biotransformation Reactions of Drugs and Drug Candidates
      Emre M. Isin
      Drug Metabolism and Disposition April 2023, 51 (4) 413-426; DOI: https://doi.org/10.1124/dmd.121.000744

J

  1. Jariwala, Parth B.

    1. Relevance of Human Aldoketoreductases and Microbial β-Glucuronidases in Testosterone Disposition
      Abdul Basit, John K. Amory, Vijaya Saradhi Mettu, Cindy Yanfei Li, Scott Heyward, Parth B. Jariwala, Matthew R. Redinbo and Bhagwat Prasad
      Drug Metabolism and Disposition April 2023, 51 (4) 427-435; DOI: https://doi.org/10.1124/dmd.122.000975

  2. Johnson, Trevor N

    1. Predictive Performance of Physiologically Based Pharmacokinetic Modelling of Beta-Lactam Antibiotic Concentrations in Adipose, Bone, and Muscle Tissues
      Predictive Performance of Physiologically Based Pharmacokinetic Modelling of Beta-Lactam Antibiotic Concentrations in Adipose, Bone, and Muscle Tissues
      Pieter-Jan De Sutter, Pieter De Cock, Trevor N Johnson, Helen Musther, Elke Gasthuys and An Vermeulen
      Drug Metabolism and Disposition April 2023, 51 (4) 499-508; DOI: https://doi.org/10.1124/dmd.122.001129

  3. Jurva, Ulrik

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100
    2. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Open Access
      Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 464-479; DOI: https://doi.org/10.1124/dmd.122.001099

K

  1. Kato, Hiroaki

    1. The Unique Human N10-Glucuronidated Metabolite Formation from Olanzapine in Chimeric NOG-TKm30 Mice with Humanized Livers
      The Unique Human N10-Glucuronidated Metabolite Formation from Olanzapine in Chimeric NOG-TKm30 Mice with Humanized Livers
      Shotaro Uehara, Yuichiro Higuchi, Nao Yoneda, Hiroaki Kato, Hiroshi Yamazaki and Hiroshi Suemizu
      Drug Metabolism and Disposition April 2023, 51 (4) 480-491; DOI: https://doi.org/10.1124/dmd.122.001102

  2. Korzekwa, Ken

    1. Process and System Clearances in Pharmacokinetic Models: Our Basic Clearance Concepts Are Correct
      Ken Korzekwa and Swati Nagar
      Drug Metabolism and Disposition April 2023, 51 (4) 532-542; DOI: https://doi.org/10.1124/dmd.122.001060

L

  1. Leandersson, Carina

    1. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Open Access
      Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 464-479; DOI: https://doi.org/10.1124/dmd.122.001099

  2. Li, Cindy Yanfei

    1. Relevance of Human Aldoketoreductases and Microbial β-Glucuronidases in Testosterone Disposition
      Abdul Basit, John K. Amory, Vijaya Saradhi Mettu, Cindy Yanfei Li, Scott Heyward, Parth B. Jariwala, Matthew R. Redinbo and Bhagwat Prasad
      Drug Metabolism and Disposition April 2023, 51 (4) 427-435; DOI: https://doi.org/10.1124/dmd.122.000975

  3. Li, Qing

    1. Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs
      Haijun Yang, Yanjuan Zhang, Rong Zhou, Tianyuan Wu, Peng Zhu, Yujie Liu, Jian Zhou, Yalan Xiong, Yanling Xiong, Honghao Zhou, Wei Zhang, Yan Shu, Xiong Li and Qing Li
      Drug Metabolism and Disposition April 2023, 51 (4) 509-520; DOI: https://doi.org/10.1124/dmd.122.001173

  4. Li, Xiong

    1. Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs
      Haijun Yang, Yanjuan Zhang, Rong Zhou, Tianyuan Wu, Peng Zhu, Yujie Liu, Jian Zhou, Yalan Xiong, Yanling Xiong, Honghao Zhou, Wei Zhang, Yan Shu, Xiong Li and Qing Li
      Drug Metabolism and Disposition April 2023, 51 (4) 509-520; DOI: https://doi.org/10.1124/dmd.122.001173

  5. Li, Xue-Qing

    1. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Open Access
      Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 464-479; DOI: https://doi.org/10.1124/dmd.122.001099

  6. Lindstedt, Eva-Lotte

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100

  7. Liu, Yujie

    1. Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs
      Haijun Yang, Yanjuan Zhang, Rong Zhou, Tianyuan Wu, Peng Zhu, Yujie Liu, Jian Zhou, Yalan Xiong, Yanling Xiong, Honghao Zhou, Wei Zhang, Yan Shu, Xiong Li and Qing Li
      Drug Metabolism and Disposition April 2023, 51 (4) 509-520; DOI: https://doi.org/10.1124/dmd.122.001173

M

  1. Ma, Shuguang

    1. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
      Shuguang Ma, Sungjoon Cho, Srikumar Sahasranaman, Weiping Zhao, Jodie Pang, Xiao Ding, Brian Dean, Bin Wang, Jerry Y. Hsu, Joseph Ware and Laurent Salphati
      Drug Metabolism and Disposition April 2023, 51 (4) 436-450; DOI: https://doi.org/10.1124/dmd.122.001096

  2. Menakuru, Somasekhara R.

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100

  3. Mettu, Vijaya Saradhi

    1. Relevance of Human Aldoketoreductases and Microbial β-Glucuronidases in Testosterone Disposition
      Abdul Basit, John K. Amory, Vijaya Saradhi Mettu, Cindy Yanfei Li, Scott Heyward, Parth B. Jariwala, Matthew R. Redinbo and Bhagwat Prasad
      Drug Metabolism and Disposition April 2023, 51 (4) 427-435; DOI: https://doi.org/10.1124/dmd.122.000975

  4. Musther, Helen

    1. Predictive Performance of Physiologically Based Pharmacokinetic Modelling of Beta-Lactam Antibiotic Concentrations in Adipose, Bone, and Muscle Tissues
      Predictive Performance of Physiologically Based Pharmacokinetic Modelling of Beta-Lactam Antibiotic Concentrations in Adipose, Bone, and Muscle Tissues
      Pieter-Jan De Sutter, Pieter De Cock, Trevor N Johnson, Helen Musther, Elke Gasthuys and An Vermeulen
      Drug Metabolism and Disposition April 2023, 51 (4) 499-508; DOI: https://doi.org/10.1124/dmd.122.001129

N

  1. Nagar, Swati

    1. Process and System Clearances in Pharmacokinetic Models: Our Basic Clearance Concepts Are Correct
      Ken Korzekwa and Swati Nagar
      Drug Metabolism and Disposition April 2023, 51 (4) 532-542; DOI: https://doi.org/10.1124/dmd.122.001060

O

  1. Orsburn, Benjamin C.

    1. Open Access
      Biotransformation of Efavirenz and Proteomic Analysis of Cytochrome P450s and UDP-Glucuronosyltransferases in Mouse, Macaque, and Human Brain-Derived In Vitro Systems
      Abigail M. Wheeler, Benjamin C. Orsburn and Namandjé N. Bumpus
      Drug Metabolism and Disposition April 2023, 51 (4) 521-531; DOI: https://doi.org/10.1124/dmd.122.001195

P

  1. Pang, Jodie

    1. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
      Shuguang Ma, Sungjoon Cho, Srikumar Sahasranaman, Weiping Zhao, Jodie Pang, Xiao Ding, Brian Dean, Bin Wang, Jerry Y. Hsu, Joseph Ware and Laurent Salphati
      Drug Metabolism and Disposition April 2023, 51 (4) 436-450; DOI: https://doi.org/10.1124/dmd.122.001096

  2. Pelay-Gimeno, Marta

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100

  3. Prasad, Bhagwat

    1. Relevance of Human Aldoketoreductases and Microbial β-Glucuronidases in Testosterone Disposition
      Abdul Basit, John K. Amory, Vijaya Saradhi Mettu, Cindy Yanfei Li, Scott Heyward, Parth B. Jariwala, Matthew R. Redinbo and Bhagwat Prasad
      Drug Metabolism and Disposition April 2023, 51 (4) 427-435; DOI: https://doi.org/10.1124/dmd.122.000975

Q

  1. Qiao, Xiaomeng

    1. CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells
      Weihong Yang, Huan Zhao, Yaojie Dou, Pei Wang, Qi Chang, Xiaomeng Qiao, Xiaofei Wang, Chen Xu, Zhe Zhang and Lirong Zhang
      Drug Metabolism and Disposition April 2023, 51 (4) 492-498; DOI: https://doi.org/10.1124/dmd.122.001111

R

  1. Redinbo, Matthew R.

    1. Relevance of Human Aldoketoreductases and Microbial β-Glucuronidases in Testosterone Disposition
      Abdul Basit, John K. Amory, Vijaya Saradhi Mettu, Cindy Yanfei Li, Scott Heyward, Parth B. Jariwala, Matthew R. Redinbo and Bhagwat Prasad
      Drug Metabolism and Disposition April 2023, 51 (4) 427-435; DOI: https://doi.org/10.1124/dmd.122.000975

S

  1. Sahasranaman, Srikumar

    1. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
      Shuguang Ma, Sungjoon Cho, Srikumar Sahasranaman, Weiping Zhao, Jodie Pang, Xiao Ding, Brian Dean, Bin Wang, Jerry Y. Hsu, Joseph Ware and Laurent Salphati
      Drug Metabolism and Disposition April 2023, 51 (4) 436-450; DOI: https://doi.org/10.1124/dmd.122.001096

  2. Salphati, Laurent

    1. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
      Shuguang Ma, Sungjoon Cho, Srikumar Sahasranaman, Weiping Zhao, Jodie Pang, Xiao Ding, Brian Dean, Bin Wang, Jerry Y. Hsu, Joseph Ware and Laurent Salphati
      Drug Metabolism and Disposition April 2023, 51 (4) 436-450; DOI: https://doi.org/10.1124/dmd.122.001096

  3. Sandinge, Ann-Sofie

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100
    2. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Open Access
      Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 464-479; DOI: https://doi.org/10.1124/dmd.122.001099

  4. Shu, Yan

    1. Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs
      Haijun Yang, Yanjuan Zhang, Rong Zhou, Tianyuan Wu, Peng Zhu, Yujie Liu, Jian Zhou, Yalan Xiong, Yanling Xiong, Honghao Zhou, Wei Zhang, Yan Shu, Xiong Li and Qing Li
      Drug Metabolism and Disposition April 2023, 51 (4) 509-520; DOI: https://doi.org/10.1124/dmd.122.001173

  5. Suemizu, Hiroshi

    1. The Unique Human N10-Glucuronidated Metabolite Formation from Olanzapine in Chimeric NOG-TKm30 Mice with Humanized Livers
      The Unique Human N10-Glucuronidated Metabolite Formation from Olanzapine in Chimeric NOG-TKm30 Mice with Humanized Livers
      Shotaro Uehara, Yuichiro Higuchi, Nao Yoneda, Hiroaki Kato, Hiroshi Yamazaki and Hiroshi Suemizu
      Drug Metabolism and Disposition April 2023, 51 (4) 480-491; DOI: https://doi.org/10.1124/dmd.122.001102

  6. Sundell, Johan

    1. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Open Access
      Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 464-479; DOI: https://doi.org/10.1124/dmd.122.001099

U

  1. Uehara, Shotaro

    1. The Unique Human N10-Glucuronidated Metabolite Formation from Olanzapine in Chimeric NOG-TKm30 Mice with Humanized Livers
      The Unique Human N10-Glucuronidated Metabolite Formation from Olanzapine in Chimeric NOG-TKm30 Mice with Humanized Livers
      Shotaro Uehara, Yuichiro Higuchi, Nao Yoneda, Hiroaki Kato, Hiroshi Yamazaki and Hiroshi Suemizu
      Drug Metabolism and Disposition April 2023, 51 (4) 480-491; DOI: https://doi.org/10.1124/dmd.122.001102

V

  1. Vaes, Wouter H.J.

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100

  2. Vermeulen, An

    1. Predictive Performance of Physiologically Based Pharmacokinetic Modelling of Beta-Lactam Antibiotic Concentrations in Adipose, Bone, and Muscle Tissues
      Predictive Performance of Physiologically Based Pharmacokinetic Modelling of Beta-Lactam Antibiotic Concentrations in Adipose, Bone, and Muscle Tissues
      Pieter-Jan De Sutter, Pieter De Cock, Trevor N Johnson, Helen Musther, Elke Gasthuys and An Vermeulen
      Drug Metabolism and Disposition April 2023, 51 (4) 499-508; DOI: https://doi.org/10.1124/dmd.122.001129

W

  1. Wang, Bin

    1. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
      Shuguang Ma, Sungjoon Cho, Srikumar Sahasranaman, Weiping Zhao, Jodie Pang, Xiao Ding, Brian Dean, Bin Wang, Jerry Y. Hsu, Joseph Ware and Laurent Salphati
      Drug Metabolism and Disposition April 2023, 51 (4) 436-450; DOI: https://doi.org/10.1124/dmd.122.001096

  2. Wang, Pei

    1. CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells
      Weihong Yang, Huan Zhao, Yaojie Dou, Pei Wang, Qi Chang, Xiaomeng Qiao, Xiaofei Wang, Chen Xu, Zhe Zhang and Lirong Zhang
      Drug Metabolism and Disposition April 2023, 51 (4) 492-498; DOI: https://doi.org/10.1124/dmd.122.001111

  3. Wang, Xiaofei

    1. CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells
      Weihong Yang, Huan Zhao, Yaojie Dou, Pei Wang, Qi Chang, Xiaomeng Qiao, Xiaofei Wang, Chen Xu, Zhe Zhang and Lirong Zhang
      Drug Metabolism and Disposition April 2023, 51 (4) 492-498; DOI: https://doi.org/10.1124/dmd.122.001111

  4. Ware, Joseph

    1. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
      Shuguang Ma, Sungjoon Cho, Srikumar Sahasranaman, Weiping Zhao, Jodie Pang, Xiao Ding, Brian Dean, Bin Wang, Jerry Y. Hsu, Joseph Ware and Laurent Salphati
      Drug Metabolism and Disposition April 2023, 51 (4) 436-450; DOI: https://doi.org/10.1124/dmd.122.001096

  5. Weidolf, Lars

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100
    2. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Open Access
      Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 464-479; DOI: https://doi.org/10.1124/dmd.122.001099

  6. Westerlund, Kristina

    1. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Open Access
      Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 464-479; DOI: https://doi.org/10.1124/dmd.122.001099

  7. Wheeler, Abigail M.

    1. Open Access
      Biotransformation of Efavirenz and Proteomic Analysis of Cytochrome P450s and UDP-Glucuronosyltransferases in Mouse, Macaque, and Human Brain-Derived In Vitro Systems
      Abigail M. Wheeler, Benjamin C. Orsburn and Namandjé N. Bumpus
      Drug Metabolism and Disposition April 2023, 51 (4) 521-531; DOI: https://doi.org/10.1124/dmd.122.001195

  8. Wu, Tianyuan

    1. Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs
      Haijun Yang, Yanjuan Zhang, Rong Zhou, Tianyuan Wu, Peng Zhu, Yujie Liu, Jian Zhou, Yalan Xiong, Yanling Xiong, Honghao Zhou, Wei Zhang, Yan Shu, Xiong Li and Qing Li
      Drug Metabolism and Disposition April 2023, 51 (4) 509-520; DOI: https://doi.org/10.1124/dmd.122.001173

X

  1. Xiong, Yalan

    1. Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs
      Haijun Yang, Yanjuan Zhang, Rong Zhou, Tianyuan Wu, Peng Zhu, Yujie Liu, Jian Zhou, Yalan Xiong, Yanling Xiong, Honghao Zhou, Wei Zhang, Yan Shu, Xiong Li and Qing Li
      Drug Metabolism and Disposition April 2023, 51 (4) 509-520; DOI: https://doi.org/10.1124/dmd.122.001173

  2. Xiong, Yanling

    1. Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs
      Haijun Yang, Yanjuan Zhang, Rong Zhou, Tianyuan Wu, Peng Zhu, Yujie Liu, Jian Zhou, Yalan Xiong, Yanling Xiong, Honghao Zhou, Wei Zhang, Yan Shu, Xiong Li and Qing Li
      Drug Metabolism and Disposition April 2023, 51 (4) 509-520; DOI: https://doi.org/10.1124/dmd.122.001173

  3. Xu, Chen

    1. CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells
      Weihong Yang, Huan Zhao, Yaojie Dou, Pei Wang, Qi Chang, Xiaomeng Qiao, Xiaofei Wang, Chen Xu, Zhe Zhang and Lirong Zhang
      Drug Metabolism and Disposition April 2023, 51 (4) 492-498; DOI: https://doi.org/10.1124/dmd.122.001111

Y

  1. Yamazaki, Hiroshi

    1. The Unique Human N10-Glucuronidated Metabolite Formation from Olanzapine in Chimeric NOG-TKm30 Mice with Humanized Livers
      The Unique Human N10-Glucuronidated Metabolite Formation from Olanzapine in Chimeric NOG-TKm30 Mice with Humanized Livers
      Shotaro Uehara, Yuichiro Higuchi, Nao Yoneda, Hiroaki Kato, Hiroshi Yamazaki and Hiroshi Suemizu
      Drug Metabolism and Disposition April 2023, 51 (4) 480-491; DOI: https://doi.org/10.1124/dmd.122.001102

  2. Yan, Jingjing

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100

  3. Yang, Haijun

    1. Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs
      Haijun Yang, Yanjuan Zhang, Rong Zhou, Tianyuan Wu, Peng Zhu, Yujie Liu, Jian Zhou, Yalan Xiong, Yanling Xiong, Honghao Zhou, Wei Zhang, Yan Shu, Xiong Li and Qing Li
      Drug Metabolism and Disposition April 2023, 51 (4) 509-520; DOI: https://doi.org/10.1124/dmd.122.001173

  4. Yang, Weihong

    1. CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells
      Weihong Yang, Huan Zhao, Yaojie Dou, Pei Wang, Qi Chang, Xiaomeng Qiao, Xiaofei Wang, Chen Xu, Zhe Zhang and Lirong Zhang
      Drug Metabolism and Disposition April 2023, 51 (4) 492-498; DOI: https://doi.org/10.1124/dmd.122.001111

  5. Yoneda, Nao

    1. The Unique Human N10-Glucuronidated Metabolite Formation from Olanzapine in Chimeric NOG-TKm30 Mice with Humanized Livers
      The Unique Human N10-Glucuronidated Metabolite Formation from Olanzapine in Chimeric NOG-TKm30 Mice with Humanized Livers
      Shotaro Uehara, Yuichiro Higuchi, Nao Yoneda, Hiroaki Kato, Hiroshi Yamazaki and Hiroshi Suemizu
      Drug Metabolism and Disposition April 2023, 51 (4) 480-491; DOI: https://doi.org/10.1124/dmd.122.001102

Z

  1. Zhang, Lirong

    1. CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells
      Weihong Yang, Huan Zhao, Yaojie Dou, Pei Wang, Qi Chang, Xiaomeng Qiao, Xiaofei Wang, Chen Xu, Zhe Zhang and Lirong Zhang
      Drug Metabolism and Disposition April 2023, 51 (4) 492-498; DOI: https://doi.org/10.1124/dmd.122.001111

  2. Zhang, Wei

    1. Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs
      Haijun Yang, Yanjuan Zhang, Rong Zhou, Tianyuan Wu, Peng Zhu, Yujie Liu, Jian Zhou, Yalan Xiong, Yanling Xiong, Honghao Zhou, Wei Zhang, Yan Shu, Xiong Li and Qing Li
      Drug Metabolism and Disposition April 2023, 51 (4) 509-520; DOI: https://doi.org/10.1124/dmd.122.001173

  3. Zhang, Yanjuan

    1. Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs
      Haijun Yang, Yanjuan Zhang, Rong Zhou, Tianyuan Wu, Peng Zhu, Yujie Liu, Jian Zhou, Yalan Xiong, Yanling Xiong, Honghao Zhou, Wei Zhang, Yan Shu, Xiong Li and Qing Li
      Drug Metabolism and Disposition April 2023, 51 (4) 509-520; DOI: https://doi.org/10.1124/dmd.122.001173

  4. Zhang, Zhe

    1. CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells
      Weihong Yang, Huan Zhao, Yaojie Dou, Pei Wang, Qi Chang, Xiaomeng Qiao, Xiaofei Wang, Chen Xu, Zhe Zhang and Lirong Zhang
      Drug Metabolism and Disposition April 2023, 51 (4) 492-498; DOI: https://doi.org/10.1124/dmd.122.001111

  5. Zhao, Huan

    1. CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells
      Weihong Yang, Huan Zhao, Yaojie Dou, Pei Wang, Qi Chang, Xiaomeng Qiao, Xiaofei Wang, Chen Xu, Zhe Zhang and Lirong Zhang
      Drug Metabolism and Disposition April 2023, 51 (4) 492-498; DOI: https://doi.org/10.1124/dmd.122.001111

  6. Zhao, Weiping

    1. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
      Shuguang Ma, Sungjoon Cho, Srikumar Sahasranaman, Weiping Zhao, Jodie Pang, Xiao Ding, Brian Dean, Bin Wang, Jerry Y. Hsu, Joseph Ware and Laurent Salphati
      Drug Metabolism and Disposition April 2023, 51 (4) 436-450; DOI: https://doi.org/10.1124/dmd.122.001096

  7. Zhou, Honghao

    1. Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs
      Haijun Yang, Yanjuan Zhang, Rong Zhou, Tianyuan Wu, Peng Zhu, Yujie Liu, Jian Zhou, Yalan Xiong, Yanling Xiong, Honghao Zhou, Wei Zhang, Yan Shu, Xiong Li and Qing Li
      Drug Metabolism and Disposition April 2023, 51 (4) 509-520; DOI: https://doi.org/10.1124/dmd.122.001173

  8. Zhou, Jian

    1. Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs
      Haijun Yang, Yanjuan Zhang, Rong Zhou, Tianyuan Wu, Peng Zhu, Yujie Liu, Jian Zhou, Yalan Xiong, Yanling Xiong, Honghao Zhou, Wei Zhang, Yan Shu, Xiong Li and Qing Li
      Drug Metabolism and Disposition April 2023, 51 (4) 509-520; DOI: https://doi.org/10.1124/dmd.122.001173

  9. Zhou, Rong

    1. Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs
      Haijun Yang, Yanjuan Zhang, Rong Zhou, Tianyuan Wu, Peng Zhu, Yujie Liu, Jian Zhou, Yalan Xiong, Yanling Xiong, Honghao Zhou, Wei Zhang, Yan Shu, Xiong Li and Qing Li
      Drug Metabolism and Disposition April 2023, 51 (4) 509-520; DOI: https://doi.org/10.1124/dmd.122.001173

  10. Zhu, Peng

    1. Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs
      Haijun Yang, Yanjuan Zhang, Rong Zhou, Tianyuan Wu, Peng Zhu, Yujie Liu, Jian Zhou, Yalan Xiong, Yanling Xiong, Honghao Zhou, Wei Zhang, Yan Shu, Xiong Li and Qing Li
      Drug Metabolism and Disposition April 2023, 51 (4) 509-520; DOI: https://doi.org/10.1124/dmd.122.001173
Back to top

In this issue

Advertisement